Disse 14 patienter havde en lavere forekomst af genotype entecavir- resistens (kumulativ sandsynlighed på 18, 8% i 5 års opfølgningsperiode) end den samlede forsøgspopulation (se tabel).
These 14 patients had a lower rate of genotypic entecavir resistance (cumulative probability 18.8% through 5 years of follow-up) than the overall study population (see table).